Novartis to File for Additional Indication for Lucentis in Japan within This Year

Novartis AG of Switzerland has revealed its plan to file an application in Japan within this year for an additional indication for its anti-vascular endothelial growth factor (VEGF) treatment Lucentis (ranibizumab) for the improvement of visual acuity in patients with...read more